StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB - Free Report) from a sell rating to a hold rating in a report issued on Thursday.

Several other equities analysts also recently issued reports on MCRB. Canaccord Genuity Group reissued a "buy" rating and issued a $10.00 target price on shares of Seres Therapeutics in a research report on Thursday, November 14th. Chardan Capital restated a "buy" rating and issued a $1.25 price objective on shares of Seres Therapeutics in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $5.08.

Seres Therapeutics Stock Performance

NASDAQ MCRB traded down $0.04 on Thursday, reaching $0.73. 495,029 shares of the stock traded hands, compared to its average volume of 1,434,656. The company has a fifty day moving average price of $0.81 and a 200-day moving average price of $0.84. Seres Therapeutics has a 12 month low of $0.54 and a 12 month high of $1.53. The company has a market cap of $126.44 million, a price-to-earnings ratio of -3.16 and a beta of 2.19.

Remove Ads

Hedge Funds Weigh In On Seres Therapeutics

Several large investors have recently bought and sold shares of MCRB. Millennium Management LLC raised its stake in Seres Therapeutics by 77.2% during the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company's stock valued at $1,505,000 after acquiring an additional 788,762 shares during the last quarter. Jane Street Group LLC grew its stake in Seres Therapeutics by 181.4% in the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock valued at $49,000 after acquiring an additional 37,866 shares during the last quarter. Northern Trust Corp increased its stake in shares of Seres Therapeutics by 20.4% during the 4th quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock worth $218,000 after purchasing an additional 44,461 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Seres Therapeutics by 8.8% in the fourth quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company's stock worth $1,256,000 after acquiring an additional 121,793 shares during the last quarter. Finally, Avantax Advisory Services Inc. boosted its stake in shares of Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 28,500 shares during the last quarter. Institutional investors and hedge funds own 59.34% of the company's stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.